News and Announcements
Invigor Group (ASX: IVO) announces WeChat agreement with China’s Winning Group has been upgraded
- Published October 23, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Invigor Group (ASX: IVO) has upgraded it’s WeChat agreement with China’s Winning Group Holdings to an “unconditional” status.
- The existing agreement is now secured in place for three years.
- The unconditional status will enable the company to accelerate its growth on partnerships with Winning Group across South-East Asia.
Invigor Group (ASX: IVO) has upgraded it’s WeChat agreement with China’s Winning Group Holdings to an “unconditional” status.
Both companies have opted to waive the initial three-month pilot period and will move to live deployment of WeChat pay in South-East Asia.
The existing agreement is now secured in place for three years.
The upgraded status will enable the company to accelerate growth on partnerships with Winning Group across South-East Asia.
Winning Group is a global solutions provider for Tencent Holdings, one of China’s largest companies and one of the world’s most valued internet companies.
The deal upgrade validates the relationship between Invigor and Winning Group.
Tencent owns WeChat which is one of the most popular payment and social platforms across China.
The upgraded deal will become a significant revenue generator for Invigor as the agreement reinforces its gradual move to a transactional-based model where it will make revenue on the sales from merchants, advertising revenue from promotions and most importantly, from revenue with the integration of Invigor’s Loyalty solution.
About Invigor Group (ASX: IVO)
Invigor is a B2B insights and loyalty company for retailers, brands and venue operators that delivers a more strategic, profitable approach to today’s commerce.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
